Sarosh Nagar
Biographic Data
| ID | 8306037 |
|---|---|
| NAME | Sarosh Nagar |
| GIVEN NAMES | Sarosh |
| FAMILY NAME | Nagar |
| SIGNATURE | NAGAR S |
| AFFILIATIONS | Brigham and Women's Hospital |
| ORCID | 0000-0002-4534-6561 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
A systematic review of economic evaluations of pharmacological treatments for active tuberculosis
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022
In this cross-sectional study, simulating the drug price negotiation provisions in the Inflation Reduction Act of 2022 revealed important limitations, including strict selection criteria and the potential for drugs to become ineligible for negotiation during the 2 years between selection and prices taking effect. Despite these limitations, the policy still delivered substantial savings because ceiling prices offered steep discounts, in part, by e…
What Should US Policymakers Learn From International Drug Pricing Transparency Strategies
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation for Economic Co-operation and Development member nations: the United Kingdom, Germany, and Canada. Specifically, this article compares these countries' policies on list and net price disclosures and on how international reference pricing is used to evaluate merits and drawbacks of different pricing transparency approaches. Finally, the artic…
No prominent works on this page.
What Should US Policymakers Learn From International Drug Pricing Transparency Strategies
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation for Economic Co-operation and Development member nations: the United Kingdom, Germany, and Canada. Specifically, this article compares these countries' policies on list and net price disclosures and on how international reference pricing is used to evaluate merits and drawbacks of different pricing transparency approaches. Finally, the artic…
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022
In this cross-sectional study, simulating the drug price negotiation provisions in the Inflation Reduction Act of 2022 revealed important limitations, including strict selection criteria and the potential for drugs to become ineligible for negotiation during the 2 years between selection and prices taking effect. Despite these limitations, the policy still delivered substantial savings because ceiling prices offered steep discounts, in part, by e…
A systematic review of economic evaluations of pharmacological treatments for active tuberculosis
Actuarial science (2 works) · Business (2 works) · Economics (2 works) · Law (2 works) · Law (2 works) · Pharmaceutical Economics and Policy (2 works) · Political science (2 works) · Public economics (2 works) · Accounting (1 work) · Ceiling (cloud (1 work)